- Published on
Surgery - Meckel's Diverticulum
Introduction
A true congenital diverticulum on the ileum's antimesenteric boundary.complies with the "occurs in 2% of the population, is 2 feet from the ileocaecal valve, and is 2 inches in length" criteria.
Etiology
The omphalomesenteric/vitelline duct in an embryo joins the developing midgut and yolk sac. In the event that the duct fails to fully recede by the fifth or seventh week, it may lead to a persistent diverticulum or, less frequently, an omphalomesenteric fistula, sinus, fibrous band, or vitelline duct cyst.
Epidemiology
The most prevalent congenital abnormality of the small intestine, affecting 2% of the population, is twice as common in men than in women. Of those affected at any age, 60% have symptoms before the age of ten.
History
The most frequent incidental or asymptomatic discovery. PR bleeding, which primarily affects children, is typically painless and appears as brick-red, dark blood mixed with excrement. It can also be severe and linked to shock. abdominal pain brought on by ulceration or diverticulitis. signs of intestinal blockage brought on by intussusception or volvulus. Mucoid or purulent discharge from the umbilicus is infrequent.
Examination
Signs may not be very strong. There may be indicators of shock when there is bleeding. Inflammatory rebound or guarding discomfort can resemble acute appendicitis symptoms.
Pathogenesis
All layers of the intestine wall are present in a genuine diverticulum, which ranges in size from 0.5 to 50 cm. It is lined with small intestinal mucosa and frequently contains heterotopic tissue (found in 60% of symptomatic cases and 5% of asymptomatic cases), most frequently stomach or pancreatic mucosa (but infrequently duodenal, jejunal, or colonic). Acid secreted by the ectopic stomach mucosa might lead to erosion or bleeding.
Investigations
Bloods: FBC, U&E, clotting, crossmatch, if bleeding.
Isotope scan: If ectopic gastric mucosa is present, a Meckel's diverticulum will absorb 99mTc-pertechnetate (a negative scan does not rule it out, though). Preoperative diagnosis presents challenges. Possibly observed in experiments using barium contrast.
In case of blockage or perforation, erect the CXR and do an AXR.
Glands angiography: When bleeding is rapid, this could not be sensitive; however, it might be helpful in cases of active bleeding.
Management
Emergency (bleeding or obstruction): address fluid and electrolyte imbalances while performing resuscitation.
Surgical: Band division and/or small bowel resection combined with surgical resection (diverticulectomy). Although excision of the incidental Meckel's diverticulum can be done laparoscopically with endostaplers, there is no strong evidence to support this procedure.
Complications
All together, these conditions carry a 6% lifetime risk: hemorrhage, intussusception, enterolith, inflammation (diverticulitis), and obstruction from an internal hernia around an omphalomesenteric band.
A Meckel's diverticulum that is imprisoned is known as a Littre's hernia. There have been reports of carcinoid tumors within Meckel's diverticulum.
Prognosis
In most cases, perform well under proper supervision.
Introduction
A true congenital diverticulum on the ileum's antimesenteric boundary.complies with the "occurs in 2% of the population, is 2 feet from the ileocaecal valve, and is 2 inches in length" criteria.
Etiology
The omphalomesenteric/vitelline duct in an embryo joins the developing midgut and yolk sac. In the event that the duct fails to fully recede by the fifth or seventh week, it may lead to a persistent diverticulum or, less frequently, an omphalomesenteric fistula, sinus, fibrous band, or vitelline duct cyst.
Epidemiology
The most prevalent congenital abnormality of the small intestine, affecting 2% of the population, is twice as common in men than in women. Of those affected at any age, 60% have symptoms before the age of ten.
History
The most frequent incidental or asymptomatic discovery. PR bleeding, which primarily affects children, is typically painless and appears as brick-red, dark blood mixed with excrement. It can also be severe and linked to shock. abdominal pain brought on by ulceration or diverticulitis. signs of intestinal blockage brought on by intussusception or volvulus. Mucoid or purulent discharge from the umbilicus is infrequent.
Examination
Signs may not be very strong. There may be indicators of shock when there is bleeding. Inflammatory rebound or guarding discomfort can resemble acute appendicitis symptoms.
Pathogenesis
All layers of the intestine wall are present in a genuine diverticulum, which ranges in size from 0.5 to 50 cm. It is lined with small intestinal mucosa and frequently contains heterotopic tissue (found in 60% of symptomatic cases and 5% of asymptomatic cases), most frequently stomach or pancreatic mucosa (but infrequently duodenal, jejunal, or colonic). Acid secreted by the ectopic stomach mucosa might lead to erosion or bleeding.
Investigations
Bloods: FBC, U&E, clotting, crossmatch, if bleeding.
Isotope scan: If ectopic gastric mucosa is present, a Meckel's diverticulum will absorb 99mTc-pertechnetate (a negative scan does not rule it out, though). Preoperative diagnosis presents challenges. Possibly observed in experiments using barium contrast.
In case of blockage or perforation, erect the CXR and do an AXR.
Glands angiography: When bleeding is rapid, this could not be sensitive; however, it might be helpful in cases of active bleeding.
Management
Emergency (bleeding or obstruction): address fluid and electrolyte imbalances while performing resuscitation.
Surgical: Band division and/or small bowel resection combined with surgical resection (diverticulectomy). Although excision of the incidental Meckel's diverticulum can be done laparoscopically with endostaplers, there is no strong evidence to support this procedure.
Complications
All together, these conditions carry a 6% lifetime risk: hemorrhage, intussusception, enterolith, inflammation (diverticulitis), and obstruction from an internal hernia around an omphalomesenteric band.
A Meckel's diverticulum that is imprisoned is known as a Littre's hernia. There have been reports of carcinoid tumors within Meckel's diverticulum.
Prognosis
In most cases, perform well under proper supervision.
- Published on
Surgery - Nutrition
Introduction
Oral nutritional support: Giving out foodstuffs that have been enriched or supplements.
Enteral nutrition: Oral nutritional supplements and tube feeding via oral, nasal, or percutaneous methods are supplied through the gastrointestinal system.
Parenteral nutrition refers to the intravenous administration of liquids, electrolytes, and nutrients.
Epidemiology
About 40% of patients are admitted with malnutrition.
History
Loss of weight, decreased appetite, signs of a related disease, or consequences.
Examining the body and looking for evidence of cachexia. Weight, BMI, midarm circumference, and triceps skin-fold thickness are examples of anthropometric measures.
Pathogenesis
The first source of glucose is the breakdown of glycogen in the liver. Hepatic gluconeogenesis (using amino acids from protein breakdown and glycerol from fatty acids) takes place after 24 hours.
Glycerol and free fatty acids are released during lipolysis and are converted to ketones by the liver.
Investigational studies
nutritional screening and evaluation upon admission, albumin, calcium, magnesium, PO4, zinc, and SGA (subjective global assessment).
Management
should be overseen and managed by a multidisciplinary team that includes a medical team, SALT, and a dietician.
Indications
Oral nutritional support: indications Individuals who are considered malnourished or at risk due to low body mass index (BMI <18.5 kg/m2, unintentional weight loss >10% in the preceding 3-6 months, or a BMI <20 and unintentional weight loss >5% in the preceding 3-6 months) are included.
Enteral: sedation (in the intensive care unit), dysphagia, upper gastrointestinal blockage (tumor, stricture).
Nasojejunal: pancreatitis (improves mortality in severe cases and reduces infective consequences), limited stomach motility, restriction of the stomach outflow, patients at risk of aspiration.
Parenteral: In cases such as small bowel syndrome, high fistula, persistent ileus, or obstruction where the gastrointestinal tract is not available or functioning.
Contraindications
Enteral: Absent peristalsis, bowel obstruction, terminal illness (unless the patient requests it).
Parenteral: Renal and hepatic insufficiency, egg and soy allergy, exercise caution.
Feeds: Enteric formulas may be supplement-only or fully nutritionally replete.
Standard formulas include entire proteins, lipids (long-chain triglycerides) with or without fiber, and macro- and micronutrients. Other types of formulae include those that are tailored to a particular disease, immune-modulating, low- or high-energy, peptide-based, free amino acid (elemental), high-lipid, and highly monounsaturated fatty acid formulations.
Enteral feeding routes: feeding with a tube through a nasogastric, orogastric, nasojejunal, percutaneous endoscopic gastrostomy (PEG), PEG with jejunal extension, surgical jejunostomy, or radiologically inserted gastrostomy (RIG).
Parenteral Feeding (TPN): usually administered by central venous access, while it can also be designed for delivery via other routes. While using TPN, keeping an eye on:
& Every day: glucose, Mg2+, Ca2+, PO4, LFT, U&E,
Every week: iron and triglyceride studies.
Vitamins A and E, zinc, copper, manganese, and selenium levels every month.
Complications
The following symptoms of malnutrition include impaired wound healing, immunological dysfunction, weakness of the muscles, "susceptibility to infection, pressure sores, hospital stay, readmission rates, and mortality."
Enteral nutrition: Biochemical factors include fatty liver, poor renal function, and refeeding syndrome, a potentially catastrophic metabolic shift that occurs when patients with depleted body reserves of minerals like K, Mg, and PO4 are given a carbohydrate source.
Mechanical symptoms: nausea, vomiting, diarrhea, and stomach discomfort.
Parenteral nourishment: Related to lines: thrombosis, sepsis.
Metabolic acidosis, fatty liver and disordered LFTs, hyperglycemia, bacterial translocation, acute cholecystitis (bile stasis), and refeeding syndrome are all associated to feeding.
Prognosis
Comparatively speaking, those who are malnourished experience 2-3 times as many difficulties.
Introduction
Oral nutritional support: Giving out foodstuffs that have been enriched or supplements.
Enteral nutrition: Oral nutritional supplements and tube feeding via oral, nasal, or percutaneous methods are supplied through the gastrointestinal system.
Parenteral nutrition refers to the intravenous administration of liquids, electrolytes, and nutrients.
Epidemiology
About 40% of patients are admitted with malnutrition.
History
Loss of weight, decreased appetite, signs of a related disease, or consequences.
Examining the body and looking for evidence of cachexia. Weight, BMI, midarm circumference, and triceps skin-fold thickness are examples of anthropometric measures.
Pathogenesis
The first source of glucose is the breakdown of glycogen in the liver. Hepatic gluconeogenesis (using amino acids from protein breakdown and glycerol from fatty acids) takes place after 24 hours.
Glycerol and free fatty acids are released during lipolysis and are converted to ketones by the liver.
Investigational studies
nutritional screening and evaluation upon admission, albumin, calcium, magnesium, PO4, zinc, and SGA (subjective global assessment).
Management
should be overseen and managed by a multidisciplinary team that includes a medical team, SALT, and a dietician.
Indications
Oral nutritional support: indications Individuals who are considered malnourished or at risk due to low body mass index (BMI <18.5 kg/m2, unintentional weight loss >10% in the preceding 3-6 months, or a BMI <20 and unintentional weight loss >5% in the preceding 3-6 months) are included.
Enteral: sedation (in the intensive care unit), dysphagia, upper gastrointestinal blockage (tumor, stricture).
Nasojejunal: pancreatitis (improves mortality in severe cases and reduces infective consequences), limited stomach motility, restriction of the stomach outflow, patients at risk of aspiration.
Parenteral: In cases such as small bowel syndrome, high fistula, persistent ileus, or obstruction where the gastrointestinal tract is not available or functioning.
Contraindications
Enteral: Absent peristalsis, bowel obstruction, terminal illness (unless the patient requests it).
Parenteral: Renal and hepatic insufficiency, egg and soy allergy, exercise caution.
Feeds: Enteric formulas may be supplement-only or fully nutritionally replete.
Standard formulas include entire proteins, lipids (long-chain triglycerides) with or without fiber, and macro- and micronutrients. Other types of formulae include those that are tailored to a particular disease, immune-modulating, low- or high-energy, peptide-based, free amino acid (elemental), high-lipid, and highly monounsaturated fatty acid formulations.
Enteral feeding routes: feeding with a tube through a nasogastric, orogastric, nasojejunal, percutaneous endoscopic gastrostomy (PEG), PEG with jejunal extension, surgical jejunostomy, or radiologically inserted gastrostomy (RIG).
Parenteral Feeding (TPN): usually administered by central venous access, while it can also be designed for delivery via other routes. While using TPN, keeping an eye on:
& Every day: glucose, Mg2+, Ca2+, PO4, LFT, U&E,
Every week: iron and triglyceride studies.
Vitamins A and E, zinc, copper, manganese, and selenium levels every month.
Complications
The following symptoms of malnutrition include impaired wound healing, immunological dysfunction, weakness of the muscles, "susceptibility to infection, pressure sores, hospital stay, readmission rates, and mortality."
Enteral nutrition: Biochemical factors include fatty liver, poor renal function, and refeeding syndrome, a potentially catastrophic metabolic shift that occurs when patients with depleted body reserves of minerals like K, Mg, and PO4 are given a carbohydrate source.
Mechanical symptoms: nausea, vomiting, diarrhea, and stomach discomfort.
Parenteral nourishment: Related to lines: thrombosis, sepsis.
Metabolic acidosis, fatty liver and disordered LFTs, hyperglycemia, bacterial translocation, acute cholecystitis (bile stasis), and refeeding syndrome are all associated to feeding.
Prognosis
Comparatively speaking, those who are malnourished experience 2-3 times as many difficulties.
- Published on
Surgery - Peritonitis
Introduction
Inflammation of the abdominal cavity's peritoneal lining is known as peritonitis, and it can be either localized or widespread, with the latter being either primary or secondary.
Etiology
Localized: Cholecystitis, diverticulitis, appendicitis, and salpingitis are common causes.
Primary generalized: Peritoneal cavity infection caused by bacteria that isn't clearly focused on one area. Children may develop primary pneumococcal peritonitis as a result of Streptococcus penumoniae. In adults, frequently linked to renal failure patients receiving CAPD (continuous ambulatory peritoneal dialysis) or cirrhosis and ascites (spontaneous bacterial peritonitis).
Secondary generalized: Peptic ulcers, ruptured peptic ulcers, pancreatic discharges (a chemical kind of peritonitis that frequently becomes secondary infected), and other localized infective foci that are either polymicrobial (see above) or nonbacterial.
Epidemiology
While secondary generalized and localized peritonitis are more common, primary peritonitis is uncommon and typically manifests in adolescent females.
History
A thorough history should be obtained, covering the genesis, character, progression, and dissemination of the abdominal pain in addition to aggravating, mitigating, and concomitant events. As a result of movement and coughing, parietal pain from peritonitis is typically constant, intense, localized, and made worse (parietal peritoneum is supplied by somatic A-d fibres emanating from spinal neurons of T7–L2).
Examination
Examine vital signs, indicators of dehydration, and evidence of reduced perfusion (from hypovolemia, sepsis, or circulatory failure, for example).
Regionalized: Tenderness accompanied with involuntary guarding: reflex contraction of the muscles covering the abdominal wall; rebound tenderness: pain resulting from the inflamed peritoneum moving when a palpating hand is suddenly removed; this is also exhibited by percussion tenderness or pain triggered by coughing.
Generalized: Movement makes the patient's discomfort worse; they are typically extremely ill with systemic symptoms of toxaemia or sepsis (such as fever, tachycardia). Due to paralytic ileus, the belly is rigid with widespread rebound and guarding, and bowel sounds are either attenuated or usually nonexistent.
Investigational studies
as demonstrated by the clinical evaluation and history.
Blood tests include FBC, U&Es, LFT, amylase, CRP, coagulation, G&S or crossmatch, blood cultures, and ABG (which looks for respiratory failure, lactate accumulation, or metabolic acidosis).
For pneumoperitoneum, erect CXR.
AXR: For blockage of the bowel.
Laparoscopy or CT abdomen: To identify the peritonitis's etiology. The peritoneum becomes erythematous and loses its glossy aspect when it is inflamed. This is due to the creation of a large amount of serous inflammatory exudate, which is rich in protein, inflammatory mediators, and white blood cells. The larger omentum adheres to the irritated organ, preventing the infection from spreading.
If ascites: Gram stain, culture, ascitic tap and cell count (diagnostic of SBP if >250 neutrophils/mm3).
Management
Localized: The course of treatment will be determined by the underlying cause (appendicitis, for example), as well as IV antibiotics (cholecystitis, salpingitis, and the majority of cases of acute diverticulitis).
Generalized: Sepsis and shock could cause the patient to die. Requires IV fluid replacement, volume and electrolyte imbalance correction, and IV antibiotics. CVP line, NG tube, and urinary catheter to track fluid balance and determine the need for surgery.
Emergency laparotomy/laparoscopy: To determine the cause, treat it, remove any necrotic or infected tissue, and make a large amount of peritoneal lavage. An acute non-necrotizing pancreatitis would be an exception.
Antibiotics are used to treat primary peritonitis, but this diagnosis is frequently made only after an effort at surgical intervention has been made.
Complications
Early: Portal pyaemia/hepatic abscesses, wound infection, tertiary peritonitis (persistence of intra-abdominal infection), paralytic ileus, septic shock, respiratory or multi-organ failure.
Late: adhesions and incisional hernia.
Prognosis
Localized peritonitis typically goes away when the underlying cause is treated appropriately.
The mortality rate for generalized peritonitis is substantially higher, at about 30–50%. The death rate may rise to more than 70% if septic shock or multi-organ failure develops concurrently.
With the right antibiotic therapy, the prognosis for primary peritonitis is favorable. Patients with SBP may have a total mortality risk of more than 30% if diagnosis and treatment are put off.
Introduction
Inflammation of the abdominal cavity's peritoneal lining is known as peritonitis, and it can be either localized or widespread, with the latter being either primary or secondary.
Etiology
Localized: Cholecystitis, diverticulitis, appendicitis, and salpingitis are common causes.
Primary generalized: Peritoneal cavity infection caused by bacteria that isn't clearly focused on one area. Children may develop primary pneumococcal peritonitis as a result of Streptococcus penumoniae. In adults, frequently linked to renal failure patients receiving CAPD (continuous ambulatory peritoneal dialysis) or cirrhosis and ascites (spontaneous bacterial peritonitis).
Secondary generalized: Peptic ulcers, ruptured peptic ulcers, pancreatic discharges (a chemical kind of peritonitis that frequently becomes secondary infected), and other localized infective foci that are either polymicrobial (see above) or nonbacterial.
Epidemiology
While secondary generalized and localized peritonitis are more common, primary peritonitis is uncommon and typically manifests in adolescent females.
History
A thorough history should be obtained, covering the genesis, character, progression, and dissemination of the abdominal pain in addition to aggravating, mitigating, and concomitant events. As a result of movement and coughing, parietal pain from peritonitis is typically constant, intense, localized, and made worse (parietal peritoneum is supplied by somatic A-d fibres emanating from spinal neurons of T7–L2).
Examination
Examine vital signs, indicators of dehydration, and evidence of reduced perfusion (from hypovolemia, sepsis, or circulatory failure, for example).
Regionalized: Tenderness accompanied with involuntary guarding: reflex contraction of the muscles covering the abdominal wall; rebound tenderness: pain resulting from the inflamed peritoneum moving when a palpating hand is suddenly removed; this is also exhibited by percussion tenderness or pain triggered by coughing.
Generalized: Movement makes the patient's discomfort worse; they are typically extremely ill with systemic symptoms of toxaemia or sepsis (such as fever, tachycardia). Due to paralytic ileus, the belly is rigid with widespread rebound and guarding, and bowel sounds are either attenuated or usually nonexistent.
Investigational studies
as demonstrated by the clinical evaluation and history.
Blood tests include FBC, U&Es, LFT, amylase, CRP, coagulation, G&S or crossmatch, blood cultures, and ABG (which looks for respiratory failure, lactate accumulation, or metabolic acidosis).
For pneumoperitoneum, erect CXR.
AXR: For blockage of the bowel.
Laparoscopy or CT abdomen: To identify the peritonitis's etiology. The peritoneum becomes erythematous and loses its glossy aspect when it is inflamed. This is due to the creation of a large amount of serous inflammatory exudate, which is rich in protein, inflammatory mediators, and white blood cells. The larger omentum adheres to the irritated organ, preventing the infection from spreading.
If ascites: Gram stain, culture, ascitic tap and cell count (diagnostic of SBP if >250 neutrophils/mm3).
Management
Localized: The course of treatment will be determined by the underlying cause (appendicitis, for example), as well as IV antibiotics (cholecystitis, salpingitis, and the majority of cases of acute diverticulitis).
Generalized: Sepsis and shock could cause the patient to die. Requires IV fluid replacement, volume and electrolyte imbalance correction, and IV antibiotics. CVP line, NG tube, and urinary catheter to track fluid balance and determine the need for surgery.
Emergency laparotomy/laparoscopy: To determine the cause, treat it, remove any necrotic or infected tissue, and make a large amount of peritoneal lavage. An acute non-necrotizing pancreatitis would be an exception.
Antibiotics are used to treat primary peritonitis, but this diagnosis is frequently made only after an effort at surgical intervention has been made.
Complications
Early: Portal pyaemia/hepatic abscesses, wound infection, tertiary peritonitis (persistence of intra-abdominal infection), paralytic ileus, septic shock, respiratory or multi-organ failure.
Late: adhesions and incisional hernia.
Prognosis
Localized peritonitis typically goes away when the underlying cause is treated appropriately.
The mortality rate for generalized peritonitis is substantially higher, at about 30–50%. The death rate may rise to more than 70% if septic shock or multi-organ failure develops concurrently.
With the right antibiotic therapy, the prognosis for primary peritonitis is favorable. Patients with SBP may have a total mortality risk of more than 30% if diagnosis and treatment are put off.
- Published on
Pathology - Turner Syndrome
caused by either whole or partial X chromosomal monosomy (XO karyotype without Barr body).
Aortic coarctation, bicuspid aortic valve, and other congenital heart defects; infantile genitalia and breasts; short stature with a broad chest and widely dispersed nipples; lymphedema of extremities; primary amenorrhea and infertility with replacement of ovaries with fibrous strands (no ova or follicles).
Patients have a higher chance of acquiring osteoporosis, hypertension, diabetes mellitus, and Hashimoto thyroiditis.
Results from the lab: lower synthesis of estrogen and higher amounts of FSH and LH.
Handling
Growth hormone (to treat low height); replacement of estrogen.
reduced life expectancy as a result of irregularities in the heart.
caused by either whole or partial X chromosomal monosomy (XO karyotype without Barr body).
Aortic coarctation, bicuspid aortic valve, and other congenital heart defects; infantile genitalia and breasts; short stature with a broad chest and widely dispersed nipples; lymphedema of extremities; primary amenorrhea and infertility with replacement of ovaries with fibrous strands (no ova or follicles).
Patients have a higher chance of acquiring osteoporosis, hypertension, diabetes mellitus, and Hashimoto thyroiditis.
Results from the lab: lower synthesis of estrogen and higher amounts of FSH and LH.
Handling
Growth hormone (to treat low height); replacement of estrogen.
reduced life expectancy as a result of irregularities in the heart.
- Published on
Pathology - Fragile X Syndrome
caused by an increase in CGG repeats on the X chromosome's family mental retardation (FMRJ) gene.
affects both sexes (1:2000), while the clinical symptoms are typically milder in females.
A severe developmental delay accompanied by autistic traits, a long face with enormous ears and jaw, macroorchidism (giant testicles), a connective tissue disorder resulting in prolapsed mitral valve and hyperextensible joints, seizures, and strabismus.
genetic guidance.
Although there is no impact on lifespan, lifelong supervision is necessary.
Huntington disease, myotonic dystrophy, and fragile X syndrome all exhibit anticipation, a condition in which the frequency of repetitions rises with each generation and causes increasingly severe illness symptoms.
caused by an increase in CGG repeats on the X chromosome's family mental retardation (FMRJ) gene.
affects both sexes (1:2000), while the clinical symptoms are typically milder in females.
A severe developmental delay accompanied by autistic traits, a long face with enormous ears and jaw, macroorchidism (giant testicles), a connective tissue disorder resulting in prolapsed mitral valve and hyperextensible joints, seizures, and strabismus.
genetic guidance.
Although there is no impact on lifespan, lifelong supervision is necessary.
Huntington disease, myotonic dystrophy, and fragile X syndrome all exhibit anticipation, a condition in which the frequency of repetitions rises with each generation and causes increasingly severe illness symptoms.
- Published on
Surgery - Breast Abscess
Abscess in the breast
Introduction
localized infection in which the breast tissue collects pus. Puerperal (lactational) and non-puerperal are the two basic types.
Etiology
Lactational stasis: An infection linked to milk stasis, usually caused by coagulase-negative Staphylococcus aureus bacteria.
Non-puerperal: anaerobes such as S. aureus and enterococci, frequently Bacteroides spp.; rare causes include TB and actinomycosis. Exclusions should be made for smoking, periductal mastitis/mammary duct ectasia, and related inflammatory breast cancer. Associated with diabetes, steroid medication, and wound infections following breast surgery.
Epidemiology
Breast abscesses caused by lactation are frequent and usually develop shortly after the breast is partially emptied, causing engorgement and stasis, throughout the weaning process. Non-lactational abscesses are more common in smokers and those between the ages of 30 and 60.
History
The patient reports pain and the emergence of an uncomfortable swelling in a breast area. She might report feeling sick and having a temperature.
Women who develop a non-puerperal abscess frequently have a history of prior infections, and their systemic disturbance is typically less.
Examination
Local: There is swelling, warmth, and tenderness in the breast region. An inspection of the nipple may reveal fractures or fissures; the skin above it may be irritated. In non-puerperal cases, there can be indications of duct ectasia, such as nipple retraction, or scars or tissue distortion from prior occurrences.
Systemic: tachycardia, pyrexia.
Investigational studies
Imaging consists of ultrasound and aspiration for pus sample sensitivity, culture, and microscopy.
Management
Medical: Antibiotics can be used to treat early cellulitic phase abscesses (flucloxacillin for lactational abscesses, and metronidazole in non-puerperal abscesses). Often emptying your breasts to avoid milk stasis.
Operative: Breastfeeding mothers may benefit from daily needle aspiration covered with antibiotics.
Larger abscesses (>5 cm) are only appropriate for formal incision and drainage. Loculi are investigated and broken down; the incision should be cosmetically pleasing and allow for complete drainage. The incision can be sealed with primary closure or gently packed and kept open each day. Breastfeeding should proceed from the unaffected breast while the afflicted breast is emptied using a breast pump or by hand. suggestions for preventing cracked nipples.
Non-puerperal: Open drainage needs to be avoided or done with a tiny cut.
After the infection has subsided, the affected duct system should be excised as the last course of treatment.
Complications
sluggish wound healing, trouble nursing, unsatisfactory cosmetic result, and the development of mammary fistulas; necrosis of the skin above seldom occurs.
Prognosis
A breast abscess will eventually develop and discharge spontaneously onto the skin's surface if left untreated. Abscesses that are not puerperal often reoccur.
Abscess in the breast
Introduction
localized infection in which the breast tissue collects pus. Puerperal (lactational) and non-puerperal are the two basic types.
Etiology
Lactational stasis: An infection linked to milk stasis, usually caused by coagulase-negative Staphylococcus aureus bacteria.
Non-puerperal: anaerobes such as S. aureus and enterococci, frequently Bacteroides spp.; rare causes include TB and actinomycosis. Exclusions should be made for smoking, periductal mastitis/mammary duct ectasia, and related inflammatory breast cancer. Associated with diabetes, steroid medication, and wound infections following breast surgery.
Epidemiology
Breast abscesses caused by lactation are frequent and usually develop shortly after the breast is partially emptied, causing engorgement and stasis, throughout the weaning process. Non-lactational abscesses are more common in smokers and those between the ages of 30 and 60.
History
The patient reports pain and the emergence of an uncomfortable swelling in a breast area. She might report feeling sick and having a temperature.
Women who develop a non-puerperal abscess frequently have a history of prior infections, and their systemic disturbance is typically less.
Examination
Local: There is swelling, warmth, and tenderness in the breast region. An inspection of the nipple may reveal fractures or fissures; the skin above it may be irritated. In non-puerperal cases, there can be indications of duct ectasia, such as nipple retraction, or scars or tissue distortion from prior occurrences.
Systemic: tachycardia, pyrexia.
Investigational studies
Imaging consists of ultrasound and aspiration for pus sample sensitivity, culture, and microscopy.
Management
Medical: Antibiotics can be used to treat early cellulitic phase abscesses (flucloxacillin for lactational abscesses, and metronidazole in non-puerperal abscesses). Often emptying your breasts to avoid milk stasis.
Operative: Breastfeeding mothers may benefit from daily needle aspiration covered with antibiotics.
Larger abscesses (>5 cm) are only appropriate for formal incision and drainage. Loculi are investigated and broken down; the incision should be cosmetically pleasing and allow for complete drainage. The incision can be sealed with primary closure or gently packed and kept open each day. Breastfeeding should proceed from the unaffected breast while the afflicted breast is emptied using a breast pump or by hand. suggestions for preventing cracked nipples.
Non-puerperal: Open drainage needs to be avoided or done with a tiny cut.
After the infection has subsided, the affected duct system should be excised as the last course of treatment.
Complications
sluggish wound healing, trouble nursing, unsatisfactory cosmetic result, and the development of mammary fistulas; necrosis of the skin above seldom occurs.
Prognosis
A breast abscess will eventually develop and discharge spontaneously onto the skin's surface if left untreated. Abscesses that are not puerperal often reoccur.
- Published on
Surgery - Breast Cancer
Overview
Cancer that originates in the breast tissue.
Origin
a mix of environmental and genetic variables.
Genetics: 5–10% of instances are due to genetic factors, but the majority are polygenic risk. 2% of cases contain BRCA-1 (17q) and BRCA-2 (13q) gene mutations, with carriers having a lifetime risk of up to 87%. Li-Fraumeni syndrome (TP53), Cowden's syndrome (PTEN), Peutz-Jeghers syndrome (STK11/LKB1), ataxia-telagiectasia (ATM), and Muir-Torre syndrome (MSH2/MLH1) are examples of rare hereditary breast cancer syndromes.
Risk factors include age, nulliparity, early menarche, late menopause, menopausal hormone replacement medication, obesity, alcohol consumption, and extended exposure to female sex hormones, especially oestrogen.
Epidemiology is the second most common cause of cancer-related deaths in women worldwide, after lung cancer in the United States. In the UK, the lifetime risk is 1 in 9. peak incidence in people aged 40 to 70. Just 1% of all breast cancers in men are rare.
History
perhaps found by screening.
Primary symptoms include breast lumps, which are typically painless, breast form alterations, and nipple discharge.
Axillary lump, bone pain, weight loss, and paraneoplastic disorders (such as cerebellar syndrome) are signs of secondary spread.
Examination
When the patient is supine and upright, the breasts should be examined for asymmetry, peau d'orange (oedema), dimpling or tethering, nipple scaling or inversion, or, in more severe situations, ulceration.
Use a clockwise radial approach for palpating hard, irregular, or fixed lumps.
Check for hepatomegaly, chest anomalies, palpable axillary lymph nodes, supraclavicular lymph nodes, and bone discomfort.
Investigations
Triple assessment: A standardized procedure that includes a clinical evaluation, imaging (MRI, CT, or mammography), and tissue diagnosis (cytology or biopsy) to investigate a breast lump.
Mammography (Fig. 1): A valuable screening tool for women over 35. In the UK, screening doesn't start until beyond age 50. The craniocaudal and mediolateral oblique views are typical. Spiculated lesions and branching or linear microcalcifications are characteristics of malignancy.
Ultrasound: To distinguish between dangerous solid lesions and benign cystic lesions. More beneficial for women under 35.
Fine-needle aspiration: Less invasive, enables cyst drainage and cytology of individual breast masses.
Core biopsy: Allows for histological diagnosis; can be image guided.
Sentinel lymph node biopsy: After injecting radioactive tracer or blue dye in the vicinity of the breast lesion, a nuclear scan locates the sentinel node, which is then biopsied to look for spread.
CT (chest, abdomen, pelvis), PET, or bone scans for metastases are the staging options.
Blood: CA-15-3 tumor marker, bone profile, LFT, FBC, U&Es, and Ca2₠.
Histopathology:
In situ cancer:non-invasive ductal or lobular carcinoma in situ (DCIS, LCIS) that preserves the basement membrane.
Invasive: Ductal carcinoma accounts for 75% of all breast cancer cases.
Other: tubular, mucinous, medullary, cruriform, papillary, lobular (10–15%, Indian filing arrangement of cells), and Paget's disease of the nipple (ductal carcinoma in situ infiltrating the nipple).
Phlloides: Fibroepithelial tumours that can be benign or malignant.
Molecular prognostic factors: Oestrogen and progesterone receptors (ER, PR) and HER-2
expression (20–30% of cancers) are valuable prognostic indicators and guide treatment.
Flow cytometry measures DNA content (ploidy) and S-phase fraction (cell proliferation
rate).
Grading: The Nottingham modification of the Bloom and Richardson grading system is a
prognostic indicator. Three features assessed are tubule formation, nuclear size/
pleomorphism and number of mitoses. Scores are used to generate Grades 1 (well
differentiated) to 3 (poorly differentiated).
Staging: The UICC TNM-staging system.
Tumour size (T): T1: <2 cm; T2: 2–5 cm; T3: >5 cm; T4: any size with chest wall or skin
extension.
Nodes (N): N1: mobile ipsilateral axillary; N2: fixed ipsilateral axillary; N3: ipsilateral internal
mammary nodes.
Metastases (M): M0: no distant metastases; M1: distant metastases.
Supervisory
Breast care nurses, radiologists, oncologists, and breast surgeons are all part of the multidisciplinary management team. The size, location, type, stage, and consideration of each patient's unique wishes all play a role in the decision to remove the cancer surgically.
Breast-conserving surgery: Segmental mastectomy or wide local excision (if the patient is willing to receive radiation therapy and the single cancer is less than 5 cm). Radiological wire localization can be required for smaller lesions.
Modified radical mastectomy: dissection of the axillary lymph nodes and total mastectomy.
Axillary surgery is required for node staging and can vary from level III clearance (lymph nodes up to and above the pectoralis minor muscle) to sentinel node biopsy, which removes three nodes on average.
Breast reconstruction: Usually done after the surgery, but sometimes it happens right away after surgical excision. Techniques include transverse rectus abdominis myocutaneous flaps, latissimus dorsi flaps, and breast prosthesis.
Radiotherapy: After breast-conserving surgery, external beam radiation is sometimes used as neoadjuvant therapy and to palliate advanced tumors.
Chemotherapy: Adjuvant, palliative, and neoadjuvant settings are possible for treatment. Visceral involvement, oestrogen receptor-negative tumors, fast-progressing illness, or failure of hormonal therapy are more common in premenopausal women.
Combination therapy regimens, such as those involving cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), are customized for each patient.
The primary first-line treatment for oestrogen receptor-positive tumors is hormonal therapy, which includes selective oestrogen receptor modulators like tamoxifen. Additional options include ovarian ablation using LHRH analogs, such as goserelin, aromatase inhibitors in postmenopausal women, such as letrozole or anastrozole, and selective oestrogen receptor downregulators, such as progestins and fullvestrant.
Biological therapy: In nodal and HER-2-positive cancer, trastuzumab (Herceptin), a monoclonal antibody that targets the HER-2 receptor (a cell growth promoter), is used in conjunction with chemotherapy and has been demonstrated to increase overall and disease-free survival.
Complications
significant physical or psychological damage following surgery or diagnosis.
Hypercalcemia, spinal cord compression, bone pain, and problems with the abdomen, lungs, or brain can all result from metastases.
Venous thrombosis and endometrial cancer are caused by tamoxifen. Osteoporosis, joint/muscle pain, aromatase inhibitors. The cardiotoxicity of herceptin.
Following surgery, there may be a local recurrence, wound infection, hemorrhage, lymphoedema, shoulder pain, sensory loss (the intercostobrachial nerve is frequently sacrificed, resulting in numbness in the inner, upper arm).
Fatigue, skin alterations, and lymphoedema are side effects of radiation therapy.
Prognosis varies according on stage, grade, and kind. Total 5-year survival is 100% if the illness is limited to the breast, 50%–90% if it is node-positive, and 20% if it has spread to distant organs.tumors of the fibroepithelium that may be benign or cancerous.
& HER-2 expression (20–30% of malignancies) and oestrogen and progesterone receptors (ER, PR) are important prognostic markers that help determine treatment.
DNA content (ploidy) and S-phase fraction (cell proliferation rate) are measured by flow cytometry.
Grading: A prognostic indicator is the Nottingham version of the Bloom and Richardson grading system. Nuclear size/pleomorphism, quantity of mitoses, and tubule development are the three characteristics that are evaluated. Grades 1 (highly differentiated) through 3 (poorly differentiated) are created using scores.
UICC TNM-staging system is used for staging.
Tumor size (T): <2 cm for T1, 2–5 cm for T2, >5 cm for T3, and any size with skin or chest wall expansion for T4.
Nodes (N): ipsilateral internal mammary nodes (N3), mobile ipsilateral axillary nodes (N1), and stationary ipsilateral axillary nodes (N2).
Metastases (M): M0 denotes no distant metastases, while M1 denotes distant metastases.
Overview
Cancer that originates in the breast tissue.
Origin
a mix of environmental and genetic variables.
Genetics: 5–10% of instances are due to genetic factors, but the majority are polygenic risk. 2% of cases contain BRCA-1 (17q) and BRCA-2 (13q) gene mutations, with carriers having a lifetime risk of up to 87%. Li-Fraumeni syndrome (TP53), Cowden's syndrome (PTEN), Peutz-Jeghers syndrome (STK11/LKB1), ataxia-telagiectasia (ATM), and Muir-Torre syndrome (MSH2/MLH1) are examples of rare hereditary breast cancer syndromes.
Risk factors include age, nulliparity, early menarche, late menopause, menopausal hormone replacement medication, obesity, alcohol consumption, and extended exposure to female sex hormones, especially oestrogen.
Epidemiology is the second most common cause of cancer-related deaths in women worldwide, after lung cancer in the United States. In the UK, the lifetime risk is 1 in 9. peak incidence in people aged 40 to 70. Just 1% of all breast cancers in men are rare.
History
perhaps found by screening.
Primary symptoms include breast lumps, which are typically painless, breast form alterations, and nipple discharge.
Axillary lump, bone pain, weight loss, and paraneoplastic disorders (such as cerebellar syndrome) are signs of secondary spread.
Examination
When the patient is supine and upright, the breasts should be examined for asymmetry, peau d'orange (oedema), dimpling or tethering, nipple scaling or inversion, or, in more severe situations, ulceration.
Use a clockwise radial approach for palpating hard, irregular, or fixed lumps.
Check for hepatomegaly, chest anomalies, palpable axillary lymph nodes, supraclavicular lymph nodes, and bone discomfort.
Investigations
Triple assessment: A standardized procedure that includes a clinical evaluation, imaging (MRI, CT, or mammography), and tissue diagnosis (cytology or biopsy) to investigate a breast lump.
Mammography (Fig. 1): A valuable screening tool for women over 35. In the UK, screening doesn't start until beyond age 50. The craniocaudal and mediolateral oblique views are typical. Spiculated lesions and branching or linear microcalcifications are characteristics of malignancy.
Ultrasound: To distinguish between dangerous solid lesions and benign cystic lesions. More beneficial for women under 35.
Fine-needle aspiration: Less invasive, enables cyst drainage and cytology of individual breast masses.
Core biopsy: Allows for histological diagnosis; can be image guided.
Sentinel lymph node biopsy: After injecting radioactive tracer or blue dye in the vicinity of the breast lesion, a nuclear scan locates the sentinel node, which is then biopsied to look for spread.
CT (chest, abdomen, pelvis), PET, or bone scans for metastases are the staging options.
Blood: CA-15-3 tumor marker, bone profile, LFT, FBC, U&Es, and Ca2₠.
Histopathology:
In situ cancer:non-invasive ductal or lobular carcinoma in situ (DCIS, LCIS) that preserves the basement membrane.
Invasive: Ductal carcinoma accounts for 75% of all breast cancer cases.
Other: tubular, mucinous, medullary, cruriform, papillary, lobular (10–15%, Indian filing arrangement of cells), and Paget's disease of the nipple (ductal carcinoma in situ infiltrating the nipple).
Phlloides: Fibroepithelial tumours that can be benign or malignant.
Molecular prognostic factors: Oestrogen and progesterone receptors (ER, PR) and HER-2
expression (20–30% of cancers) are valuable prognostic indicators and guide treatment.
Flow cytometry measures DNA content (ploidy) and S-phase fraction (cell proliferation
rate).
Grading: The Nottingham modification of the Bloom and Richardson grading system is a
prognostic indicator. Three features assessed are tubule formation, nuclear size/
pleomorphism and number of mitoses. Scores are used to generate Grades 1 (well
differentiated) to 3 (poorly differentiated).
Staging: The UICC TNM-staging system.
Tumour size (T): T1: <2 cm; T2: 2–5 cm; T3: >5 cm; T4: any size with chest wall or skin
extension.
Nodes (N): N1: mobile ipsilateral axillary; N2: fixed ipsilateral axillary; N3: ipsilateral internal
mammary nodes.
Metastases (M): M0: no distant metastases; M1: distant metastases.
Supervisory
Breast care nurses, radiologists, oncologists, and breast surgeons are all part of the multidisciplinary management team. The size, location, type, stage, and consideration of each patient's unique wishes all play a role in the decision to remove the cancer surgically.
Breast-conserving surgery: Segmental mastectomy or wide local excision (if the patient is willing to receive radiation therapy and the single cancer is less than 5 cm). Radiological wire localization can be required for smaller lesions.
Modified radical mastectomy: dissection of the axillary lymph nodes and total mastectomy.
Axillary surgery is required for node staging and can vary from level III clearance (lymph nodes up to and above the pectoralis minor muscle) to sentinel node biopsy, which removes three nodes on average.
Breast reconstruction: Usually done after the surgery, but sometimes it happens right away after surgical excision. Techniques include transverse rectus abdominis myocutaneous flaps, latissimus dorsi flaps, and breast prosthesis.
Radiotherapy: After breast-conserving surgery, external beam radiation is sometimes used as neoadjuvant therapy and to palliate advanced tumors.
Chemotherapy: Adjuvant, palliative, and neoadjuvant settings are possible for treatment. Visceral involvement, oestrogen receptor-negative tumors, fast-progressing illness, or failure of hormonal therapy are more common in premenopausal women.
Combination therapy regimens, such as those involving cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), are customized for each patient.
The primary first-line treatment for oestrogen receptor-positive tumors is hormonal therapy, which includes selective oestrogen receptor modulators like tamoxifen. Additional options include ovarian ablation using LHRH analogs, such as goserelin, aromatase inhibitors in postmenopausal women, such as letrozole or anastrozole, and selective oestrogen receptor downregulators, such as progestins and fullvestrant.
Biological therapy: In nodal and HER-2-positive cancer, trastuzumab (Herceptin), a monoclonal antibody that targets the HER-2 receptor (a cell growth promoter), is used in conjunction with chemotherapy and has been demonstrated to increase overall and disease-free survival.
Complications
significant physical or psychological damage following surgery or diagnosis.
Hypercalcemia, spinal cord compression, bone pain, and problems with the abdomen, lungs, or brain can all result from metastases.
Venous thrombosis and endometrial cancer are caused by tamoxifen. Osteoporosis, joint/muscle pain, aromatase inhibitors. The cardiotoxicity of herceptin.
Following surgery, there may be a local recurrence, wound infection, hemorrhage, lymphoedema, shoulder pain, sensory loss (the intercostobrachial nerve is frequently sacrificed, resulting in numbness in the inner, upper arm).
Fatigue, skin alterations, and lymphoedema are side effects of radiation therapy.
Prognosis varies according on stage, grade, and kind. Total 5-year survival is 100% if the illness is limited to the breast, 50%–90% if it is node-positive, and 20% if it has spread to distant organs.tumors of the fibroepithelium that may be benign or cancerous.
& HER-2 expression (20–30% of malignancies) and oestrogen and progesterone receptors (ER, PR) are important prognostic markers that help determine treatment.
DNA content (ploidy) and S-phase fraction (cell proliferation rate) are measured by flow cytometry.
Grading: A prognostic indicator is the Nottingham version of the Bloom and Richardson grading system. Nuclear size/pleomorphism, quantity of mitoses, and tubule development are the three characteristics that are evaluated. Grades 1 (highly differentiated) through 3 (poorly differentiated) are created using scores.
UICC TNM-staging system is used for staging.
Tumor size (T): <2 cm for T1, 2–5 cm for T2, >5 cm for T3, and any size with skin or chest wall expansion for T4.
Nodes (N): ipsilateral internal mammary nodes (N3), mobile ipsilateral axillary nodes (N1), and stationary ipsilateral axillary nodes (N2).
Metastases (M): M0 denotes no distant metastases, while M1 denotes distant metastases.
- Published on
Surgery - Benign Breast Disease
Definition
breast diseases that are not cancerous, such as physiopathological abnormalities of the adipose, stromal, epithelial, or vascular components of the breast.
Fibroadenoma: Occurs when a breast lobule hyperplasia occurs and comprises both normal connective tissue and epithelial cells.
Fat necrosis: Amorphous material, inflammatory cells, including foreign body giant cells, and irregular and necrotic adipocytes can all resemble cancer.
A normal involution is aberrated in sclerosing adenosis.
Duct ectasia: This condition is brought about by central ducts becoming dilated with secretions; if leaking into periductal tissue happens, it can result in periductal mastitis, an inflammatory response.
Origin
Under endocrine regulation, breast tissue changes in a variety of ways. Trauma is the secondary cause of fat necrosis. Benign conditions are mapped using the ANDI (aberrations of normal development and involution) classification system based on the degree of abnormality as well as the pathophysiology.
Risk Factors
possibly less common in people using birth control pills. One risk factor for periductal masttitis is smoking.
The study of epidemiology
Only 10–20% of instances are thought to proceed to a histopathological diagnosis. As many as 60% of women have diffuse fibrocystic alterations, and 70% of them have mastalgia.
Breast cysts are more prevalent in people 40 to 50 years old, and fibroadenomas are more common in people 15 to 25 years old. Unless a woman is on hormone replacement therapy (HRT), these conditions often go away after menopause.
History
Past history of lump or enlargement, breast pain or discomfort (cyclical or non-cyclical mastalgia).
Breast discharge: cancer should be suspected if it is bloodstained. It is important to determine risk factors for breast cancer, such as menstruation history, family history, pregnancy history, usage of OCP, and hormone replacement treatment.
Examination
Breast nodules, focal or widespread.
Typically, fibroadenomas are smooth, well-circumscribed, and movable lumps that have a diameter of 1-2 cm in breast mice.
Nipple discharge that is yellow or green (duct ectasia).
There are no signs of malignancy, such as dimpling, peau d'orange skin changes, or swollen lymph nodes in the arms.
Investigational studies
Typically carried out in conjunction with triple assessment:
1. A clinical assessment.
2. Imaging: USS in younger patients (<35 years old) or mammography (craniocaudal and oblique mediolateral views, spot compression and magnification views). Less frequently, benign lumps will become calcified (microcalcifications strongly signal malignancy). MRI examinations are also beneficial.
3. Cytology/Histology: By trucut or excision biopsy, or by FNA (fine-needle aspiration) cytology.
Conservative management includes treating the symptoms, such as analgesia and mastalgia with evening primrose oil, which is a rich source of gammalinoleic acid. Tips for eating a lower-fat diet and using supportive bras.Danazol is applied as a backup therapy. 17-a-ethinyl testosterone inhibits the production of ovarian steroids, reduces gonadotropin release, and stops the LH surge.
If fibroadenomas are significant or the patient requests it, they can be removed or treated cautiously.
Simple cysts should totally vanish after aspiration and don't require aspiration unless clinically required. In the absence of that, treat it like a breast lump.
Surgery: This involves removing or excising the breast lump through biopsy; if there is any reason to suspect that the lump is not benign, a broad local excision should be carried out. The treatment for intraductal papillomas is microdochectomy. In duct ectasia, the Hadfields (or Adairs) procedure excises the central ducts.
Complications
Pain reappearance.
The prognosis is good, although recurrence is frequent. Fibroadenomas: women with simple FA do not have an elevated risk of cancer, nor is there a higher family history of breast cancer.
Definition
breast diseases that are not cancerous, such as physiopathological abnormalities of the adipose, stromal, epithelial, or vascular components of the breast.
Fibroadenoma: Occurs when a breast lobule hyperplasia occurs and comprises both normal connective tissue and epithelial cells.
Fat necrosis: Amorphous material, inflammatory cells, including foreign body giant cells, and irregular and necrotic adipocytes can all resemble cancer.
A normal involution is aberrated in sclerosing adenosis.
Duct ectasia: This condition is brought about by central ducts becoming dilated with secretions; if leaking into periductal tissue happens, it can result in periductal mastitis, an inflammatory response.
Origin
Under endocrine regulation, breast tissue changes in a variety of ways. Trauma is the secondary cause of fat necrosis. Benign conditions are mapped using the ANDI (aberrations of normal development and involution) classification system based on the degree of abnormality as well as the pathophysiology.
Risk Factors
possibly less common in people using birth control pills. One risk factor for periductal masttitis is smoking.
The study of epidemiology
Only 10–20% of instances are thought to proceed to a histopathological diagnosis. As many as 60% of women have diffuse fibrocystic alterations, and 70% of them have mastalgia.
Breast cysts are more prevalent in people 40 to 50 years old, and fibroadenomas are more common in people 15 to 25 years old. Unless a woman is on hormone replacement therapy (HRT), these conditions often go away after menopause.
History
Past history of lump or enlargement, breast pain or discomfort (cyclical or non-cyclical mastalgia).
Breast discharge: cancer should be suspected if it is bloodstained. It is important to determine risk factors for breast cancer, such as menstruation history, family history, pregnancy history, usage of OCP, and hormone replacement treatment.
Examination
Breast nodules, focal or widespread.
Typically, fibroadenomas are smooth, well-circumscribed, and movable lumps that have a diameter of 1-2 cm in breast mice.
Nipple discharge that is yellow or green (duct ectasia).
There are no signs of malignancy, such as dimpling, peau d'orange skin changes, or swollen lymph nodes in the arms.
Investigational studies
Typically carried out in conjunction with triple assessment:
1. A clinical assessment.
2. Imaging: USS in younger patients (<35 years old) or mammography (craniocaudal and oblique mediolateral views, spot compression and magnification views). Less frequently, benign lumps will become calcified (microcalcifications strongly signal malignancy). MRI examinations are also beneficial.
3. Cytology/Histology: By trucut or excision biopsy, or by FNA (fine-needle aspiration) cytology.
Conservative management includes treating the symptoms, such as analgesia and mastalgia with evening primrose oil, which is a rich source of gammalinoleic acid. Tips for eating a lower-fat diet and using supportive bras.Danazol is applied as a backup therapy. 17-a-ethinyl testosterone inhibits the production of ovarian steroids, reduces gonadotropin release, and stops the LH surge.
If fibroadenomas are significant or the patient requests it, they can be removed or treated cautiously.
Simple cysts should totally vanish after aspiration and don't require aspiration unless clinically required. In the absence of that, treat it like a breast lump.
Surgery: This involves removing or excising the breast lump through biopsy; if there is any reason to suspect that the lump is not benign, a broad local excision should be carried out. The treatment for intraductal papillomas is microdochectomy. In duct ectasia, the Hadfields (or Adairs) procedure excises the central ducts.
Complications
Pain reappearance.
The prognosis is good, although recurrence is frequent. Fibroadenomas: women with simple FA do not have an elevated risk of cancer, nor is there a higher family history of breast cancer.
- Published on
Surgery - Lung Cancer
Introduction
lung primary malignant tumor. The WHO classifies bronchocarcinoma as: Adenocarcinoma, large-cell carcinoma, squamous cell carcinoma, and adenosquamous carcinoma are classified as small cell (20%) and non-small cell (80%).
Etiology
Lung tumors in their primary form: It is believed that factors including asbestos exposure and smoking, whether active or passive, eventually produce in genetic alterations that promote neoplastic transformation.
Tumors typically originate in the main or lobar bronchi (refer to Fig. 2), whereas adenocarcinomas typically manifest in distant locations.
supplementary tumors One common location for metastases is the lung.
Risk Factors
Cigarette smoking, air pollution, occupational exposures (polycyclic hydrocarbons, asbestos, nickel, chromium, cadmium, radon).
Epidemiology
The most prevalent deadly cancer in the West (18% of all cancer fatalities globally), accounting for 35,000 annual deaths in the UK, and three times more common in men than in women.
H HISTORY
5% of cases may show no symptoms despite radiological abnormalities.
Primary cause: Chest discomfort, cough, hemoptysis, and recurrent pneumonia.
Owing to local invasion: For instance, palpitations (arrhythmias), hoarseness and a cow cough caused by the left recurrent laryngeal nerve, dysphagia in the oesophagus, and brachial plexus (Pancoast's tumor).
Weight loss, exhaustion, bone pain or fractures, fits—all may be signs of metastatic disease or paraneoplastic events.
History and Examination
It's possible that none exist.
monophonic wheeze that is fixed.
indications of a pleural effusion or lobar collapse.
symptoms of metastases, such as hepatomegaly or supraclavicular lymphadenopathy.
Horner syndrome.
Investigations
Diagnosis options include sputum cytology, CT or ultrasound-guided percutaneous biopsy, lymph node biopsy, bronchoscopy with brushings or biopsy, and CXR.
TNM staging: Using CT or MRI scans of the head, abdomen, and chest, as well as bone and PET scans, is based on tumor size, nodal involvement, and metastatic metastasis. It is possible to employ invasive techniques like video-assisted thoracoscopy or mediastinoscopy.
Blood: FBC, U&Es, Ca2+ ("bone metastases"), AlkPhos, and LFT. Hypercalcemia is a prevalent condition.
Pre-operative care includes an assessment of general anesthesia, V/Q scan, ECG, and echocardiography, as well as pulmonary function testing (FEV1 >80% anticipated to tolerate a pneumonectomy; lung resection is contraindicated if FEV1 <30% predicted).
Management
Multidisciplinary conversation about the best course of treatment and tumor staging. Resectibility of the tumor (stage I and II disease, specifically IIIa) and operability (if a patient is fit enough to undertake surgery) are important factors to take into account (surgery is not recommended for small-cell cancer). It is essential to have an open dialogue with the patient regarding the risks, advantages, and prognosis. Surgery is only considered in 14% of instances.
Surgery.
Anesthesia: The lung to be operated on is isolated from the ventilatory circuit using a double-lumen endotracheal tube. The lung that will be operated on has a central line inserted ipsilaterally.
The location of the urine catheter and arterial line. To provide effective regional analgesia, a thoracic epidural catheter is frequently inserted. Method: When a bronchial tumor is detected, a rigid bronchoscopy is conducted after anesthesia is administered. Prophylactic antibiotic usage is made. With the patient in a lateral decubitus position, a posterolateral thoracotomy is typically performed with gradual rib distraction. The lung is moved, the tumor's location is determined, and the lymph nodes are examined. The pulmonary artery, vein, and bronchial tree branches are located, and if necessary, a lobectomy is carried out (60 percent of resections). Both the upper and lower lobes of the right lung can be preserved during a bilobectomy. Pneumonectomy, which entails partial resection and rebuilding of the bronchi, is avoided with sleeve resection. Pneumonectomy: one lung is removed in 25 percent of resections.
Air is drained via the front apical drain, while blood or fluid is drained via the posterior basal drain.
Unoperable: Multimodality treatment that combines chemotherapy and radiation therapy increases survival.
Docetaxel is frequently utilized. Erlotinib, an inhibitor of the epidermal growth factor receptor (EGFR), is a biological therapy used as a second-line chemotherapy drug.
Palliative and end-of-life care: includes endobronchial stents, laser treatment for bronchial tumors, problem management, and pain relief.
Complications
Metastases (usually liver, bone, and brain), pleural effusion, pulmonary hemorrhage, lobar or lung collapse, local invasion (e.g., brachial plexus, sympathetic chain, recurrent laryngeal nerve, SVC), and paraneoplastic syndromes (especially common in small-cell carcinomas, e.g., SIADH or ectopic ACTH production; squamous cell carcinomas are associated with hypercalcaemia of malignancy).
Surgery: lesion not surgically resectable (should be less than 5%).
Lobectomy: Reoperations are occasionally necessary due to frequent air leakage.
Pneumonectomy carries a high risk of cardiac arrhythmias, failure or MI, pneumonia and atelectasis, pulmonary oedema, bronchopleural fistula, hemorrhage, and pulmonary embolus. It also carries a significant physiological strain.
Prognosis
Depending on the situation, but not very good. When small-cell carcinoma first manifests, it frequently has spread. 5-year survival rate overall is less than 5%. 25% of patients survive five years after resection for early-stage illness. Pneumonectomy mortality is 8%, but lobectomy mortality is less than 2%.
Introduction
lung primary malignant tumor. The WHO classifies bronchocarcinoma as: Adenocarcinoma, large-cell carcinoma, squamous cell carcinoma, and adenosquamous carcinoma are classified as small cell (20%) and non-small cell (80%).
Etiology
Lung tumors in their primary form: It is believed that factors including asbestos exposure and smoking, whether active or passive, eventually produce in genetic alterations that promote neoplastic transformation.
Tumors typically originate in the main or lobar bronchi (refer to Fig. 2), whereas adenocarcinomas typically manifest in distant locations.
supplementary tumors One common location for metastases is the lung.
Risk Factors
Cigarette smoking, air pollution, occupational exposures (polycyclic hydrocarbons, asbestos, nickel, chromium, cadmium, radon).
Epidemiology
The most prevalent deadly cancer in the West (18% of all cancer fatalities globally), accounting for 35,000 annual deaths in the UK, and three times more common in men than in women.
H HISTORY
5% of cases may show no symptoms despite radiological abnormalities.
Primary cause: Chest discomfort, cough, hemoptysis, and recurrent pneumonia.
Owing to local invasion: For instance, palpitations (arrhythmias), hoarseness and a cow cough caused by the left recurrent laryngeal nerve, dysphagia in the oesophagus, and brachial plexus (Pancoast's tumor).
Weight loss, exhaustion, bone pain or fractures, fits—all may be signs of metastatic disease or paraneoplastic events.
History and Examination
It's possible that none exist.
monophonic wheeze that is fixed.
indications of a pleural effusion or lobar collapse.
symptoms of metastases, such as hepatomegaly or supraclavicular lymphadenopathy.
Horner syndrome.
Investigations
Diagnosis options include sputum cytology, CT or ultrasound-guided percutaneous biopsy, lymph node biopsy, bronchoscopy with brushings or biopsy, and CXR.
TNM staging: Using CT or MRI scans of the head, abdomen, and chest, as well as bone and PET scans, is based on tumor size, nodal involvement, and metastatic metastasis. It is possible to employ invasive techniques like video-assisted thoracoscopy or mediastinoscopy.
Blood: FBC, U&Es, Ca2+ ("bone metastases"), AlkPhos, and LFT. Hypercalcemia is a prevalent condition.
Pre-operative care includes an assessment of general anesthesia, V/Q scan, ECG, and echocardiography, as well as pulmonary function testing (FEV1 >80% anticipated to tolerate a pneumonectomy; lung resection is contraindicated if FEV1 <30% predicted).
Management
Multidisciplinary conversation about the best course of treatment and tumor staging. Resectibility of the tumor (stage I and II disease, specifically IIIa) and operability (if a patient is fit enough to undertake surgery) are important factors to take into account (surgery is not recommended for small-cell cancer). It is essential to have an open dialogue with the patient regarding the risks, advantages, and prognosis. Surgery is only considered in 14% of instances.
Surgery.
Anesthesia: The lung to be operated on is isolated from the ventilatory circuit using a double-lumen endotracheal tube. The lung that will be operated on has a central line inserted ipsilaterally.
The location of the urine catheter and arterial line. To provide effective regional analgesia, a thoracic epidural catheter is frequently inserted. Method: When a bronchial tumor is detected, a rigid bronchoscopy is conducted after anesthesia is administered. Prophylactic antibiotic usage is made. With the patient in a lateral decubitus position, a posterolateral thoracotomy is typically performed with gradual rib distraction. The lung is moved, the tumor's location is determined, and the lymph nodes are examined. The pulmonary artery, vein, and bronchial tree branches are located, and if necessary, a lobectomy is carried out (60 percent of resections). Both the upper and lower lobes of the right lung can be preserved during a bilobectomy. Pneumonectomy, which entails partial resection and rebuilding of the bronchi, is avoided with sleeve resection. Pneumonectomy: one lung is removed in 25 percent of resections.
Air is drained via the front apical drain, while blood or fluid is drained via the posterior basal drain.
Unoperable: Multimodality treatment that combines chemotherapy and radiation therapy increases survival.
Docetaxel is frequently utilized. Erlotinib, an inhibitor of the epidermal growth factor receptor (EGFR), is a biological therapy used as a second-line chemotherapy drug.
Palliative and end-of-life care: includes endobronchial stents, laser treatment for bronchial tumors, problem management, and pain relief.
Complications
Metastases (usually liver, bone, and brain), pleural effusion, pulmonary hemorrhage, lobar or lung collapse, local invasion (e.g., brachial plexus, sympathetic chain, recurrent laryngeal nerve, SVC), and paraneoplastic syndromes (especially common in small-cell carcinomas, e.g., SIADH or ectopic ACTH production; squamous cell carcinomas are associated with hypercalcaemia of malignancy).
Surgery: lesion not surgically resectable (should be less than 5%).
Lobectomy: Reoperations are occasionally necessary due to frequent air leakage.
Pneumonectomy carries a high risk of cardiac arrhythmias, failure or MI, pneumonia and atelectasis, pulmonary oedema, bronchopleural fistula, hemorrhage, and pulmonary embolus. It also carries a significant physiological strain.
Prognosis
Depending on the situation, but not very good. When small-cell carcinoma first manifests, it frequently has spread. 5-year survival rate overall is less than 5%. 25% of patients survive five years after resection for early-stage illness. Pneumonectomy mortality is 8%, but lobectomy mortality is less than 2%.
- Published on
Surgery - Pulmonary Embolism
Introduction
blockage of the pulmonary arteries, usually caused by a thrombus that entered the system from another location.
Etiology
Thrombus (rarely from the right atrium in patients with atrial fibrillation, and more than 95% originating from DVT of the lower limbs). A variety of substances, such as amniotic fluid, air, fat, tumors, and mycotic emboli from right-sided endocarditis, can also embolise to pulmonary arteries. Patients undergoing surgery, as well as those with immobility, obesity, OCP, heart failure, or cancer, are among the groups most at risk.
Epidemiology
very common, particularly in hospitalized patients; affect 10–20% of individuals with proximal DVT that has been verified.
History
Depending on the pulmonary embolus's size and location. Minimal: Could show no symptoms. Moderate: Cough, hemoptysis, pleuritic chest discomfort, and sudden onset dyspnea. Large (or proximal): All of the previous symptoms plus abrupt death, shock, collapse, acute right heart failure, or severe central pleuritic chest discomfort. Pulmonary hypertension symptoms include multiple minor recurring episodes.
Examination
Evaluation of clinical probability: Different scores can be used to estimate probability and direct management and additional research. Apply regional regulations.
Introduction
blockage of the pulmonary arteries, usually caused by a thrombus that entered the system from another location.
Etiology
Thrombus (rarely from the right atrium in patients with atrial fibrillation, and more than 95% originating from DVT of the lower limbs). A variety of substances, such as amniotic fluid, air, fat, tumors, and mycotic emboli from right-sided endocarditis, can also embolise to pulmonary arteries. Patients undergoing surgery, as well as those with immobility, obesity, OCP, heart failure, or cancer, are among the groups most at risk.
Epidemiology
very common, particularly in hospitalized patients; affect 10–20% of individuals with proximal DVT that has been verified.
History
Depending on the pulmonary embolus's size and location. Minimal: Could show no symptoms. Moderate: Cough, hemoptysis, pleuritic chest discomfort, and sudden onset dyspnea. Large (or proximal): All of the previous symptoms plus abrupt death, shock, collapse, acute right heart failure, or severe central pleuritic chest discomfort. Pulmonary hypertension symptoms include multiple minor recurring episodes.
Examination
Evaluation of clinical probability: Different scores can be used to estimate probability and direct management and additional research. Apply regional regulations.
Investigational studies
Low probability: Use the blood test known as the D-dimer (sensitive but insensitive to cross-linked fibrin breakdown products). High probability: Imaging is necessary. Further preliminary inquiries: Blood: Think of a thrombophilia screen, ABG. ECG: May be normal, however tachycardia, right axis deviation, or RBBB are more frequently seen. Classical patterns such as SI, QIII, or TIII are not very prevalent. CXR: Usually normal, but check for other differential diagnosis. Spiral CT pulmonary angiogram: The preferred initial diagnostic procedure. Very sensitive for medium-to large-sized emboli, but poor sensitivity for tiny emboli. Inhaling krypton-81 gas and administering IV 99mTc macro-aggregated albumin constitute the ventilation-perfusion (VQ) scan. This shows where there may be a mismatch between perfusion and ventilation. Not appropriate because to interpretation difficulties if there is a concurrent lung disease or an abnormal CXR. The gold standard for pulmonary angiography is invasive. seldom required. To check for venous thrombosis, do a lower limb Doppler ultrasound. Right heart strain may be seen on an echocardiogram.
Management
Primary prevention: Heparin prophylaxis in at-risk individuals (e.g., those undergoing surgery) and graduated pressure stockings (TEDs). prompt mobilization and sufficient hydration following surgery. If the patient's blood pressure is stable, they should start on O2, anticoagulate with heparin or LMW heparin, and switch to oral warfarin medication (INR 2-3) for at least three months. drugs that reduce pain. If hemodynamically unstable (massive PE): If cardiac arrest is likely, resuscitate, provide oxygen, IV fluid resuscitation, and thrombolysis with tissue plasminogen activator (tPA) may be considered solely on the basis of clinical considerations. Embolectomy, either surgical or radiological (where thrombolysis is contraindicated). When anticoagulation is contraindicated or for recurrent pulmonary emboli, IVC filters (such as the Greenfield filter) may be placed.
Complications
Right heart failure, pulmonary hypertension, death, and pulmonary infarction.
Prognosis
30% of deaths go untreated, 8% are treated (because of recurring emboli or underlying disease). "Risk of future thrombo-embolic disease" is present in patients.
Low probability: Use the blood test known as the D-dimer (sensitive but insensitive to cross-linked fibrin breakdown products). High probability: Imaging is necessary. Further preliminary inquiries: Blood: Think of a thrombophilia screen, ABG. ECG: May be normal, however tachycardia, right axis deviation, or RBBB are more frequently seen. Classical patterns such as SI, QIII, or TIII are not very prevalent. CXR: Usually normal, but check for other differential diagnosis. Spiral CT pulmonary angiogram: The preferred initial diagnostic procedure. Very sensitive for medium-to large-sized emboli, but poor sensitivity for tiny emboli. Inhaling krypton-81 gas and administering IV 99mTc macro-aggregated albumin constitute the ventilation-perfusion (VQ) scan. This shows where there may be a mismatch between perfusion and ventilation. Not appropriate because to interpretation difficulties if there is a concurrent lung disease or an abnormal CXR. The gold standard for pulmonary angiography is invasive. seldom required. To check for venous thrombosis, do a lower limb Doppler ultrasound. Right heart strain may be seen on an echocardiogram.
Management
Primary prevention: Heparin prophylaxis in at-risk individuals (e.g., those undergoing surgery) and graduated pressure stockings (TEDs). prompt mobilization and sufficient hydration following surgery. If the patient's blood pressure is stable, they should start on O2, anticoagulate with heparin or LMW heparin, and switch to oral warfarin medication (INR 2-3) for at least three months. drugs that reduce pain. If hemodynamically unstable (massive PE): If cardiac arrest is likely, resuscitate, provide oxygen, IV fluid resuscitation, and thrombolysis with tissue plasminogen activator (tPA) may be considered solely on the basis of clinical considerations. Embolectomy, either surgical or radiological (where thrombolysis is contraindicated). When anticoagulation is contraindicated or for recurrent pulmonary emboli, IVC filters (such as the Greenfield filter) may be placed.
Complications
Right heart failure, pulmonary hypertension, death, and pulmonary infarction.
Prognosis
30% of deaths go untreated, 8% are treated (because of recurring emboli or underlying disease). "Risk of future thrombo-embolic disease" is present in patients.
